PT  - JOURNAL ARTICLE
AU  - Kratochvil, Michael J.
AU  - Kaber, Gernot
AU  - Cai, Pamela C.
AU  - Burgener, Elizabeth B.
AU  - Barlow, Graham L.
AU  - Nicolls, Mark R.
AU  - Ozawa, Michael G.
AU  - Regula, Donald P.
AU  - Pacheco-Navarro, Ana E.
AU  - Milla, Carlos E.
AU  - Nagy, Nadine
AU  - Yang, Samuel
AU  - ,
AU  - Rogers, Angela J.
AU  - Spakowitz, Andrew J.
AU  - Heilshorn, Sarah C.
AU  - Bollyky, Paul L.
TI  - Biochemical and Biophysical Characterization of Respiratory Secretions in Severe SARS-CoV-2 (COVID-19) Infections
AID  - 10.1101/2020.09.11.20191692
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.09.11.20191692
4099  - http://medrxiv.org/content/early/2021/08/19/2020.09.11.20191692.short
4100  - http://medrxiv.org/content/early/2021/08/19/2020.09.11.20191692.full
AB  - Thick, viscous respiratory secretions are a major pathogenic feature of COVID-19 disease, but the composition and physical properties of these secretions are poorly understood. We characterized the composition and rheological properties (i.e. resistance to flow) of respiratory secretions collected from intubated COVID-19 patients. We found the percent solids and protein content are all greatly elevated in COVID-19 compared to heathy control samples and closely resemble levels seen in cystic fibrosis (CF), a genetic disease known for thick, tenacious respiratory secretions. DNA and hyaluronan are major components of respiratory secretions in COVID-19 and are likewise abundant in cadaveric lung tissues from these patients. COVID-19 secretions exhibited heterogeneous rheological behaviors with thicker samples showing increased sensitivity to DNase and hyaluronidase treatment. These results highlight the dramatic biophysical properties of COVID-19 respiratory secretions and suggest that DNA and hyaluronan may be viable therapeutic targets in COVID-19 infection.Competing Interest StatementThe authors have filed a patent on the use of 4-methylumbelliferone, an inhibitor of hyaluronan synthesis in acute respiratory distress syndrome and COVID-19 infection.Funding StatementThis research program is supported by a grant from the Stanford Innovative Medicines Accelerator program. The Stanford ICU Biobank and A.J.R. are funded by NIH/ NHLBI K23 HL125663. A.R. was supported by NIH grant T32 AI007502-23. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Stanford University IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll primary data is available upon request.